COPD Clinical Trials

The lung specialists and researchers at Cedars-Sinai are constantly working to understand pulmonary conditions and leverage new diagnostic technologies and minimally invasive surgical techniques for adults and children. As a patient at Cedars-Sinai, you can participate in clinical trials and take advantage of these medical advancements in the diagnosis and treatment of chronic obstructive pulmonary disease (COPD) and related conditions.

Questions? See the Clinical Trials FAQs.

Condition:

A1PI deficiency

Key Inclusion Criteria

  • For subjects who will undergo bronchoscopy/BAL procedures: 18 to 75 years old at time of screening
  • For subjects who will be waived from undergoing bronchoscopy/BAL procedures: At least 18 years old at the time of screening
  • Must have at least one of the following: clinical diagnosis of emphysema, evidence of emphysema and/or evidence of airway obstruction which is not completely reversed with bronchodilator treatment at the time of screening

Summary:

This study focuses on patients who have an inherited disorder called severe alpha1- proteinase inhibitor (A1PI) deficiency, also known as alpha1-antitrypsin (AAT) deficiency. A1PI is a protein that is normally present in the body to help protect the lungs. A1PI deficiency may lead to damage to lung tissue, which worsens over time and may develop into chronic obstructive pulmonary disease (COPD). The purpose of the study is to evaluate the investigational use of a drug called GLASSIA and to determine whether there are any differences in symptoms and side effects when patients receive this drug with a higher particle count or lower particle count (number of protein clusters). Researchers also aim to learn how the immune system may react to  the drug and whether GLASSIA can increase the level of A1PI in the lungs.